4-(trifluoromethyl)benzamide, also known as 4-trifluoromethylbenzamide, is a synthetic compound that has been investigated for its potential biological and pharmacological activities. It is a derivative of benzamide, a class of compounds known for their diverse medicinal properties. The trifluoromethyl group, a common substituent in medicinal chemistry, is believed to contribute to the compound's enhanced lipophilicity and metabolic stability, potentially improving its pharmacokinetic profile. While specific details about its synthesis and effects might vary depending on the research context, studies have explored its potential as a:
- **Antimicrobial agent:** Some research suggests that 4-(trifluoromethyl)benzamide exhibits antimicrobial activity against certain bacteria and fungi.
- **Anti-inflammatory agent:** Its potential anti-inflammatory effects have been investigated in various models.
- **Anti-cancer agent:** Research has explored its potential as a chemotherapeutic agent, targeting specific cancer cells.
- **Other potential applications:** Its unique chemical structure has also led to investigations for other applications, such as in materials science and organic electronics.
The study of 4-(trifluoromethyl)benzamide is driven by its potential to contribute to the development of novel drugs and materials with valuable therapeutic and industrial applications.'
| ID Source | ID |
|---|---|
| PubMed CID | 74684 |
| CHEMBL ID | 4065573 |
| SCHEMBL ID | 171651 |
| SCHEMBL ID | 8261011 |
| MeSH ID | M0110348 |
| Synonym |
|---|
| TIMTEC1_004897 |
| p-trifluoromethylbenzamide |
| 4-(trifluoromethyl)benzamide , |
| 1891-90-3 |
| nsc-160490 |
| nsc160490 |
| HMS1547O13 |
| AKOS001740657 |
| STK788406 |
| p-(trifluoromethyl)benzamide |
| A813306 |
| ctd99shh2s , |
| para-(trifluoromethyl)benzamide |
| nsc 160490 |
| einecs 217-571-9 |
| unii-ctd99shh2s |
| FT-0616909 |
| SCHEMBL171651 |
| T3474 |
| 4-trifluoromethylbenzamide |
| 4-trifluoromethyl-benzamide |
| SCHEMBL8261011 |
| benzamide, 4-(trifluoromethyl)- |
| n-(4-trifluoromethyl)benzamide |
| 4-cf3-c6h4conh2 |
| W-107749 |
| PS-8414 |
| DTXSID70172304 |
| SR-01000530647-1 |
| sr-01000530647 |
| mfcd00007998 |
| LR5 , |
| SY035534 |
| Z33546478 |
| CS-W015961 |
| renmbwixvkjjcc-uhfffaoysa-n |
| CHEMBL4065573 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1657795 | Octanol/water partition coefficient, log D of the compound at pH 2 | 2020 | Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13 | Phosphine Oxides from a Medicinal Chemist's Perspective: Physicochemical and |
| AID1657803 | Aqueous solubility of the compound in pH 6.8 buffer incubated for 24 hrs under shaking condition by UV-HPLC analysis | 2020 | Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13 | Phosphine Oxides from a Medicinal Chemist's Perspective: Physicochemical and |
| AID1425980 | Solubility of the compound in acetonitrile/water mixture at 10 mM measured after 24 by HPLC-UV method | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and in vitro Parameters Relevant for Drug Discovery. |
| AID1657804 | Equilibrium thermodynamic aqueous solubility of the compound in pH 6.8 buffer incubated for 24 hrs by UV-spectroscopy based shake flask method | 2020 | Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13 | Phosphine Oxides from a Medicinal Chemist's Perspective: Physicochemical and |
| AID1657806 | Efflux ratio of permeability in human Caco2 cells measured up to 2 hrs by LC-MS/MS analysis or scintillation counting method | 2020 | Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13 | Phosphine Oxides from a Medicinal Chemist's Perspective: Physicochemical and |
| AID1425973 | Octanol-water partition coefficient, log P of the compound at pH 10 to 11 by HPLC analysis | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and in vitro Parameters Relevant for Drug Discovery. |
| AID1425981 | Equilibrium thermodynamic aqueous solubility of the compound at 0.5 to 5 mg after 2 to 24 hrs by shake flask method | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and in vitro Parameters Relevant for Drug Discovery. |
| AID1657805 | Permeability across apical to basolateral side in human Caco2 cells measured up to 2 hrs by LC-MS/MS analysis or scintillation counting method | 2020 | Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13 | Phosphine Oxides from a Medicinal Chemist's Perspective: Physicochemical and |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.03) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||